Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative TACE + QL1706 + Lenvatinib for Resectable HCC
NCT07131501Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in hepatocellular carcinoma (HCC), sponsored by Jiangsu Provincial People's Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07131501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131501.